In our current study, we observed that preoperative trastuzumab plus chemo(immuno)therapy as neoadjuvant or conversion therapy resulted in a TRG0/1 rate of 33.3% in patients with potentially resectable stage III-IVB, HER2-positive GC, and this combination approach was well tolerated. The gene discussed is ERBB2; the disease is gastric cancer.